Patents by Inventor Dave A. Miller
Dave A. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12023343Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: GrantFiled: July 25, 2022Date of Patent: July 2, 2024Assignees: AustinPx, LLC, Board of Regents, The University of Texas SystemInventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. Dinunzio, Robert O. Williams, III
-
Publication number: 20240091201Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: November 24, 2023Publication date: March 21, 2024Applicant: AustinPx, LLCInventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
-
Patent number: 11878005Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: GrantFiled: February 6, 2019Date of Patent: January 23, 2024Assignee: AustinPx, LLCInventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
-
Publication number: 20230172949Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: ApplicationFiled: July 25, 2022Publication date: June 8, 2023Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, AustinPx, LLCInventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
-
Patent number: 11439650Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: GrantFiled: May 5, 2020Date of Patent: September 13, 2022Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLCInventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. DiNunzio, Robert O. Williams, III
-
Publication number: 20210128536Abstract: The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.Type: ApplicationFiled: October 8, 2020Publication date: May 6, 2021Applicants: DISPERSOL TECHNOLOGIES, LLC, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert O. WILLIAMS, III, Scott V. JERMAIN, Daniel Alan DAVIS, Dave A. MILLER
-
Publication number: 20200261473Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can he further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLCInventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
-
Patent number: 10668085Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: GrantFiled: June 19, 2018Date of Patent: June 2, 2020Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLCInventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. DiNunzio, Robert O. Williams, III
-
Publication number: 20200009060Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent sprying and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: May 8, 2017Publication date: January 9, 2020Applicant: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. MILLER, Daniel J. ELLENBERGER, Sandra U. SCHILLING
-
Publication number: 20190167643Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: February 6, 2019Publication date: June 6, 2019Applicant: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
-
Publication number: 20190142756Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent spraying and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: November 9, 2018Publication date: May 16, 2019Applicant: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. MILLER, Daniel J. ELLENBERGER, Sandra U. SCHILLING
-
Patent number: 10265301Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: GrantFiled: June 17, 2016Date of Patent: April 23, 2019Assignee: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
-
Patent number: 10258608Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: GrantFiled: June 28, 2017Date of Patent: April 16, 2019Assignee: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
-
Publication number: 20180360850Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: ApplicationFiled: June 19, 2018Publication date: December 20, 2018Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLCInventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
-
Patent number: 10022385Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.Type: GrantFiled: May 13, 2016Date of Patent: July 17, 2018Assignees: Board of Regents, The University of Texas System, DisperSol Technologies, LLCInventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. Dinunzio, Robert O. Williams, III
-
Publication number: 20170296514Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: June 28, 2017Publication date: October 19, 2017Applicant: DISPERSOL TECHNOLOGIES, LLCInventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
-
Patent number: 9730894Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.Type: GrantFiled: November 2, 2016Date of Patent: August 15, 2017Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Dave A. Miller, Jason T. McConville, James W. McGinity, Robert O. Williams, III
-
Publication number: 20170119669Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.Type: ApplicationFiled: November 2, 2016Publication date: May 4, 2017Inventors: Dave A. MILLER, Jason T. McCONVILLE, James W. McGINITY, Robert O. WILLIAMS, III
-
Publication number: 20170027911Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.Type: ApplicationFiled: June 17, 2016Publication date: February 2, 2017Applicant: Dispersol Technologies, LLCInventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
-
Patent number: 9504658Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.Type: GrantFiled: November 9, 2005Date of Patent: November 29, 2016Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Dave A. Miller, Jason T. McConville, James W. McGinity, Robert O. Williams, III